A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit.
about
Coenzyme Q and Its Role in the Dietary Therapy against AgingThe Role of Oxidative Stress in Neurodegenerative DiseasesOxidative Stress in Neurodegenerative DiseasesAnti-Oxidants in Parkinson's Disease Therapy: A Critical Point of ViewMitochondrial targeting of XJB-5-131 attenuates or improves pathophysiology in HdhQ150 animals with well-developed disease phenotypes.Pioglitazone in early Parkinson's disease: a phase 2, multicentre, double-blind, randomised trial.Self-reported efficacy of cannabis and other complementary medicine modalities by Parkinson's disease patients in colorado.Phase IIb Study of Intranasal Glutathione in Parkinson's DiseaseA novel design of a Phase III trial of isradipine in early Parkinson disease (STEADY-PD III).New Therapeutics to Modulate Mitochondrial Function in Neurodegenerative Disorders.Coenzyme Q10 as a Peripheral Biomarker for Multiple System AtrophyComplementary & alternative management of Parkinson's disease: an evidence-based review of eastern influenced practices.Therapeutic advances in multiple system atrophy and progressive supranuclear palsy.A randomized trial of coenzyme Q10 in patients with confirmed statin myopathyNRF2 promotes neuronal survival in neurodegeneration and acute nerve damage.Ubiquinol (reduced Coenzyme Q10) in patients with severe sepsis or septic shock: a randomized, double-blind, placebo-controlled, pilot trial.Coenzyme Q10 Levels Are Decreased in the Cerebellum of Multiple-System Atrophy Patients.Parkinson's Disease and Its Management: Part 3: Nondopaminergic and Nonpharmacological Treatment Options.Understanding the susceptibility of dopamine neurons to mitochondrial stressors in Parkinson's disease.Critical role of the Mac1/NOX2 pathway in mediating reactive microgliosis-generated chronic neuroinflammation and progressive neurodegenerationCombination therapies: The next logical Step for the treatment of synucleinopathies?Novel targets for mitochondrial medicine.Current Pharmaceutical Treatments and Alternative Therapies of Parkinson's Disease.Repurposing the NRF2 Activator Dimethyl Fumarate as Therapy Against Synucleinopathy in Parkinson's DiseaseIron Deposition Leads to Neuronal α-Synuclein Pathology by Inducing Autophagy Dysfunction.The ongoing pursuit of neuroprotective therapies in Parkinson disease.Insights on the interaction of alpha-synuclein and metals in the pathophysiology of Parkinson's disease.Redox Signaling Mediated by Thioredoxin and Glutathione Systems in the Central Nervous System.New and emerging medical therapies in Parkinson's disease.Oxidative Modification and Its Implications for the Neurodegeneration of Parkinson's Disease.Effect of Coenzyme Q10 on Biomarkers of Oxidative Stress and Cardiac Function in Hemodialysis Patients: The CoQ10 Biomarker Trial.Antioxidant modulation in restoring mitochondrial function in neurodegeneration.Nrf2: a modulator of Parkinson's disease?Ovarian ageing: the role of mitochondria in oocytes and follicles.The entangled ER-mitochondrial axis as a potential therapeutic strategy in neurodegeneration: A tangled duo unchained.Therapies for Parkinson's diseases: alternatives to current pharmacological interventions.Current and experimental treatments of Parkinson disease: A guide for neuroscientists.Gene therapy targeting mitochondrial pathway in Parkinson's disease.Coenzyme Q10 partially restores pathological alterations in a macrophage model of Gaucher disease.The c-Abl inhibitor in Parkinson disease.
P2860
Q26753050-0A6C8F6A-1024-47BE-8EA6-4C3C0FA7AC29Q26771758-4715051A-E155-4890-A91A-D135FDA32D72Q26801239-F233D3EC-CC25-4731-9A28-D55B58334376Q28084254-8CCDF2D0-D348-4829-B6CB-8ACDF26B7B67Q28386769-A4156B89-1365-41F6-A6B8-E50E2C53D3F5Q30357397-CA7D091E-E7E1-4B80-8104-4BB8538C693AQ30373216-47E959FF-F9B1-43FF-A2E3-B954A59D0C90Q33708918-E63BC8D0-2DBC-4B1F-97A4-EAF9035F90D8Q33753874-A4BA23FE-BBE5-4248-8D43-7F0979C24E14Q33783000-33EB79DD-76EC-447D-B688-100A6C81FC47Q33851721-CD7446E1-33D5-4436-A86B-F70988F7BB92Q34423275-1C9DD085-ADCA-4EB9-82B8-4F18636FA156Q34487619-C8F6ACDD-C9DC-4848-B80B-C266B6189FFCQ34982859-85EEBE88-8977-4533-B29C-23E4E788DE39Q35408649-C44262B1-B651-4352-BDF9-474C9A2A2D08Q35902883-F31CEC6C-645C-431D-88B8-0F797F2FFE0DQ35928302-61115E54-E10C-420B-BBC2-1DBFCFD8C886Q36164724-70561750-39C6-43C8-A380-59F040BA9433Q36372732-41DAE4E0-DDB6-4A9F-AB69-1DF8122A0DA2Q36474012-76442948-BD31-478D-85B8-1BA6E9873A4FQ36563062-0EB67E00-F2E1-4ED8-A6B9-D3D8D5710D3CQ36761332-3A11311C-4C4C-4ECD-8F7A-C0F4491B4D4BQ36925905-D4A927A0-B9EC-460C-9B01-46903DDD44F1Q37091371-F39EE024-1D88-40DD-A0D2-A450F8E10753Q37587232-DAEFD644-1546-4FF3-895D-622022801555Q38275171-5B6485D4-0841-4283-B320-D271A3AEECE7Q38343049-2C0C9BEA-B221-46AE-B32F-8EC193DCB3F3Q38690806-A1015C0E-5237-40CB-AA15-81566C341FC5Q38718194-0723CB5E-6A9D-4D86-A915-0816F58DD93BQ38722255-9A9735CA-7EC8-4325-A837-1D0D11144099Q38786018-D3DA0B8A-F723-4A09-96E3-1011FBC89A27Q38807381-34F984F1-A73F-4E34-882D-937776582790Q38825568-3E9EF2C6-C3C2-4CE9-B4FA-D36A61D3546AQ38827762-13A520FF-86D9-4F7C-9AD1-6947CC928057Q38841508-1FBCB6F4-92EB-4CB6-A35D-B76278E1F6A8Q38925121-0556F4D4-314D-4379-A462-26175F130DAAQ38941557-C5BC70B1-3D43-4DA4-ABC0-61EF135A2D18Q38957332-6F89D539-CC92-4465-BFDD-16D4AC65AC4CQ38976036-FA1BC885-1BEE-4397-A9A6-43E2BC07CC83Q39081447-3B9B2E50-44D8-4613-AE10-35CC9B0BE33E
P2860
A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
A randomized clinical trial of ...... sease: no evidence of benefit.
@en
type
label
A randomized clinical trial of ...... sease: no evidence of benefit.
@en
prefLabel
A randomized clinical trial of ...... sease: no evidence of benefit.
@en
P2093
P50
P1433
P1476
A randomized clinical trial of ...... sease: no evidence of benefit.
@en
P2093
Abraham N Lieberman
Adrienna Winters
Alex Rajput
Alicia Palao
Alok Sahay
Althea Silver
Andrew D Siderowf
Andrew S Feigin
Angel Figueroa
P304
P356
10.1001/JAMANEUROL.2014.131
P407
P50
P577
2014-05-01T00:00:00Z